|
カンバヤシ ハルタカ
Kanbayashi Harutaka
神林 玄隆 所属 医学部 医学科（東京女子医科大学病院） 職種 非常勤講師 |
|
| 論文種別 | 原著 |
| 言語種別 | 英語 |
| 査読の有無 | 査読なし |
| 表題 | Granulocyte and monocyte apheresis therapy for patients with active ulcerative colitis associated with COVID-19: a case report |
| 掲載誌名 | 正式名：Intestinal research 略 称：Intest Res ISSNコード：15989100/15989100 |
| 掲載区分 | 国外 |
| 巻・号・頁 | 20(1),pp.150-155 |
| 著者・共著者 | KOROKU Miki, OMORI Teppei*, KAMBAYASHI Harutaka, MURASUGI Shun, KURIYAMA Tomoko, IKARASHI Yuichi, YONEZAWA Maria, ARIMURA Ken, KARASAWA Kazunori, HANAFUSA, Norio, KAWANA Masatoshi, TOKUSHIGE Katsutoshi |
| 発行年月 | 2022/01 |
| 概要 | Coronavirus disease 2019 (COVID-19), caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is now a pandemic. Although several treatment guidelines have been proposed for patients who have both inflammatory bowel disease and COVID-19, immunosuppressive therapy is essentially not recommended, and the treatment options are limited. Even in the COVID-19 pandemic, adjuvant adsorptive granulocyte and monocyte apheresis may safely bring ulcerative colitis (UC) into remission by removing activated myeloid cells without the use of immunosuppressive therapy. Our patient was a 25-year-old Japanese male with UC and COVID-19. This is the first case report of the induction of UC remission with granulocyte and monocyte apheresis treatment for active UC associated with COVID-19. |
| DOI | 10.5217/ir.2020.00148 |
| PMID | 33902268 |